Savior or Scavenger?
Otsuka Emerges as Highest Bidder; Snags Astex for $886M in Cash
By Marie Powers
Friday, September 6, 2013
The lawyers began circling within hours of the official disclosure of the bid by Japan’s Otsuka Pharmaceutical Co. Ltd. for Astex Pharmaceuticals Inc. Days earlier, the Dublin, Calif.-based oncology drug developer reported positive top-line results from the Phase II trial of cancer candidate SGI-110 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.